Flu Clinical Trials 2024

Flu Clinical Trials 2024

Flu research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in flu clinical trials today.

Flu Clinical Trials

Here are the 6 most popular medical studies for flu

Popular filter options for flu trials

Influenza Clinical Trials

View 9 Influenza medical studies.

Atlanta, Georgia

Virus Vaccine

Inactivated Influenza A/H5N1 Vaccine for Influenza

Recruiting2 awardsPhase 1 & 2
Atlanta, Georgia

This is a single center, open-label, Phase I/II study in up to 100 adult subjects, aged 18 years and older who are at occupational risk of exposure to live H5N1 viruses. This study is designed to investigate the safety, reactogenicity, and immunogenicity of two 90 µg doses of an investigational inactivated influenza A/H5N1 virus vaccine given approximately 28 days apart. A blood sample will be collected for immunogenicity evaluation prior to each vaccination. Subjects will maintain a memory aid (appendix C4 and C13) to record oral temperature and systemic and local AEs for 7 days after immunization. Subjects will be encouraged to take their temperature around the same time each day. All subjects will receive a safety follow-up telephone call at 1 to 3 days after each vaccination (approximately Day 2) to elicit any AE and concomitant medication information. Subjects will return to the clinic 7 days after each vaccination for assessment of AEs and concomitant medications, a targeted physical examination (if indicated), and review of the memory aid. At approximately Day 28 after the first vaccination, subjects will return to the clinic for evaluation of vital signs, blood sample collection and safety follow-up, confirmation of eligibility criteria and a second vaccination. Safety follow-up will be identical to that performed after the first vaccination. At approximately Day 56 (or about 28 days after the second vaccination), subjects will return to the clinic for immunogenicity blood sample collection, AE and concomitant medication assessment, and targeted physical examination and vital sign assessment (if indicated). At approximately Day 180 (6 months after the first vaccination), subjects will return to the clinic for a final immunogenicity blood sample collection and safety assessment. Blood samples collected prior to each vaccination (Days 0 and 28) and on Days 56 and 180 after the first vaccination will be tested at the CDC Influenza Division Laboratory for the levels of neutralizing and HAI antibodies and CMI responses. The primary outcome measures will be the frequencies and severities of AEs and the GMTS and proportions of subjects who achieve 4-fold rises in serum neutralizing and HAI titers against the influenza A/H5N1 virus on Day 56. Serum HAI and neutralizing antibody responses (including frequencies of 4 fold or greater rise in titer; GMTs; and proportions of subjects achieving protective titers of neutralizing antibody 1 month and 6 months after first dose) will also be assessed. A secondary outcome measure will be CMI responses evaluated 1 month after the receipt of each dose of vaccine and 6 months after the receipt of the first dose of vaccine.
Stony Brook, New York

Group B for Influenza

Recruiting3 awardsPhase 4
Stony Brook, New York

Seasonal influenza (flu) is a significant and sometimes serious health issue in the U.S. The Centers for Disease Control (CDC) estimates that over 200,000 people are hospitalized in the U.S each year related to the flu. Public health campaigns advocate widespread vaccination for the flu, and especially for high risk people. People with cancer are high risk, with an increased risk of developing complications from the flu, such as pneumonia, bronchitis, or worsening of other medical conditions. As part of their vaccination campaign, the CDC strongly encourages inpatients to be vaccinated prior to hospital discharge. Accordingly, Stony Brook Hospital has enacted a policy that mandates screening all hospital inpatients for vaccination prior to discharge. While physicians or patients can opt not to vaccinate, the default is to proceed. Surgical oncologists have several concerns about vaccinating their patients after major surgical procedures. Patients with cancer have impaired immunity, and the ability of our patients to mount an effective immune response to the vaccine is unclear. Conversely, due to their immunocompromised state, our patients may be more susceptible to complications from the vaccine, such as influenza-like-illness (ILI), or have higher rates of postoperative complications due to the additional immune challenge of the vaccine. Previous studies have evaluated the flu vaccine in patients receiving chemotherapy, or after organ transplantation, but the combination of cancer and major surgery remains unstudied. This is a collaborative study with Infectious Diseases and Microbiology to evaluate the response to the flu vaccine in patients with pancreatic or gastric cancer, soft tissue sarcoma or peritoneal surface disease (i.e. carcinomatosis from appendiceal or colon cancers). Patients will be randomly selected to receive the vaccine either 2 weeks preoperatively or postoperatively at the time of discharge. Serum antibody response, rates of ILI and post-op complications will be analyzed. The long term goal of this study is two-fold: to determine the optimal time to vaccinate this group of patients in relation to their surgery, and to improve compliance with vaccination.

Myelodysplastic Syndrome Clinical Trials

View 6 Myelodysplastic Syndrome medical studies.

Phase 3 Flu Clinical Trials

View 82 phase 3 flu medical studies.

Paid Flu Clinical Trials

View 82 flu medical studies that offer remuneration.

Atlanta, Georgia

Virus Vaccine

Inactivated Influenza A/H5N1 Vaccine for Influenza

Recruiting2 awardsPhase 1 & 2
Atlanta, Georgia

This is a single center, open-label, Phase I/II study in up to 100 adult subjects, aged 18 years and older who are at occupational risk of exposure to live H5N1 viruses. This study is designed to investigate the safety, reactogenicity, and immunogenicity of two 90 µg doses of an investigational inactivated influenza A/H5N1 virus vaccine given approximately 28 days apart. A blood sample will be collected for immunogenicity evaluation prior to each vaccination. Subjects will maintain a memory aid (appendix C4 and C13) to record oral temperature and systemic and local AEs for 7 days after immunization. Subjects will be encouraged to take their temperature around the same time each day. All subjects will receive a safety follow-up telephone call at 1 to 3 days after each vaccination (approximately Day 2) to elicit any AE and concomitant medication information. Subjects will return to the clinic 7 days after each vaccination for assessment of AEs and concomitant medications, a targeted physical examination (if indicated), and review of the memory aid. At approximately Day 28 after the first vaccination, subjects will return to the clinic for evaluation of vital signs, blood sample collection and safety follow-up, confirmation of eligibility criteria and a second vaccination. Safety follow-up will be identical to that performed after the first vaccination. At approximately Day 56 (or about 28 days after the second vaccination), subjects will return to the clinic for immunogenicity blood sample collection, AE and concomitant medication assessment, and targeted physical examination and vital sign assessment (if indicated). At approximately Day 180 (6 months after the first vaccination), subjects will return to the clinic for a final immunogenicity blood sample collection and safety assessment. Blood samples collected prior to each vaccination (Days 0 and 28) and on Days 56 and 180 after the first vaccination will be tested at the CDC Influenza Division Laboratory for the levels of neutralizing and HAI antibodies and CMI responses. The primary outcome measures will be the frequencies and severities of AEs and the GMTS and proportions of subjects who achieve 4-fold rises in serum neutralizing and HAI titers against the influenza A/H5N1 virus on Day 56. Serum HAI and neutralizing antibody responses (including frequencies of 4 fold or greater rise in titer; GMTs; and proportions of subjects achieving protective titers of neutralizing antibody 1 month and 6 months after first dose) will also be assessed. A secondary outcome measure will be CMI responses evaluated 1 month after the receipt of each dose of vaccine and 6 months after the receipt of the first dose of vaccine.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to flu

What are the top hospitals conducting flu research?

When it comes to combating the ever-evolving flu virus, several hospitals across the United States are leading the way in clinical trials. In Birmingham, Alabama, the University of Alabama at Birmingham is making strides with three active flu trials and a total of eight conducted since their first recorded trial back in 2005. Meanwhile, in Houston's M D Anderson Cancer Center, researchers are focusing on the intersection between cancer and influenza with three ongoing studies. Although they have only recently started exploring flu trials in 2021, this renowned center is committed to uncovering new insights into this viral infection.

Heading north to Chicago brings us to GSK Investigational Site—an institution dedicated specifically to investigational research—with two active flu trials and five completed studies since its inception in 2008. Further westward lies Meridian Clinical Research, LLC based in Omaha—a facility that has been actively involved with influenza research for quite some time. With two current trials underway and an impressive twelve completed studies dating back to 2004, their contributions have proven invaluable towards understanding and finding effective treatments for the flu virus.

Lastly but not least important on our list is St. Joseph's Hospital and Medical Center located amidst Phoenix's vibrant landscape which like MD Anderson Cancer Centers just entering into conducting these crucial examinations; as recent as2022 where starting off by recording one significant breakthrough after another having already initiated two new experiments already.The dedication exhibited by these top hospitals demonstrates a commitment to tackling one of humanity's most persistent health challenges—the seasonal influenza virus—and ultimately striving toward alleviating its impact worldwide.

Which are the best cities for flu clinical trials?

When it comes to flu clinical trials, several cities emerge as prominent hubs for research. Miami, Florida leads the pack with 23 ongoing trials focusing on a variety of interventions including bivalent BNT162b2 + QIV and Quadrivalent Influenza mRNA Vaccine MRT5407. Columbus, Ohio closely follows with 14 active trials exploring topics such as quality-of-life assessment and BLI5100 High Dose. San Diego, California and Los Angeles, California both have 13 active flu trials each that investigate different treatments like Fluorouracil and Enhanced Text Reminders. Lastly, Phoenix, Arizona boasts 12 active studies examining potential breakthroughs like Quadrivalent influenza modRNA vaccine and Ofatumumab. These cities offer individuals an opportunity to participate in cutting-edge research aimed at improving flu prevention and treatment strategies.

Which are the top treatments for flu being explored in clinical trials?

Researchers are actively investigating various treatments to combat the flu in clinical trials. Among them, three leading contenders have emerged:

  • Baloxavir marboxil: Currently being explored in 8 active trials for the flu.
  • Favipiravir: Under investigation in 6 ongoing clinical trials targeting influenza.
  • Lopinavir/ritonavir: Being evaluated in 4 active studies as a potential treatment option for the flu. These promising candidates offer hope for improved management and prevention of this widespread illness.
What are the most recent clinical trials for flu?

Recent clinical trials have been conducted to explore new treatments and strategies for managing the flu. Phase 4 trial of Group i, which became available on 9/15/2023, holds promise in enhancing our understanding of the virus and its treatment options. Additionally, a Phase 3 trial called Treatment Period 1 (available from 9/5/2023) is investigating potential interventions for flu. Another noteworthy study is SPR720 (Phase 1), which became available on 8/1/2023, offering insights into novel approaches to combatting this contagious respiratory illness. These trials contribute to ongoing efforts aimed at improving prevention measures and developing more effective treatments against the flu.

What flu clinical trials were recently completed?

Several recent clinical trials have made significant strides in the field of flu research, paving the way for improved prevention and treatment options. Among these breakthroughs is a trial conducted by Seqirus, which tested the efficacy of Experimental: aIIV-B Investigational as a single intramuscular dose on Day 1, completing in August 2022. Additionally, Seqirus completed another trial involving aH5N6c on Day 22 in July 2022. Notably, FluGen Inc's Cam2020 M2SR H3N2 influenza vaccine study concluded successfully in June 2022. These trials represent important advancements that contribute to our understanding and management of flu-related illnesses.